Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation develops and markets therapies for rare cardiopulmonary and related diseases, with a pulmonary arterial hypertension franchise built around treprostinil products such as Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin and Orenitram. News commonly covers product sales, quarterly results, clinical data for pulmonary hypertension, idiopathic pulmonary fibrosis and interstitial lung disease, and updates on ralinepag and the TETON program.
The company also reports developments in manufactured-organ and transplant-support technologies, including EVLP, xenotransplantation, and Miromatrix Medical programs such as miroliverELAP and mirokidney. Governance updates, board composition, share repurchase activity and its status as a public benefit corporation are recurring corporate themes.
United Therapeutics (Nasdaq: UTHR) announced positive Phase 1 results for miroliverELAP, an external bioengineered liver developed by Miromatrix Medical. In a single-arm safety study, five acute liver failure (ALF) patients who were not transplant candidates were treated continuously for at least 44 hours; the trial met its primary endpoint of survival during treatment and reported no unexpected serious adverse events attributable to the device through 32 days of follow-up. The company will initiate a Phase 2 study and full results will be presented and published in the second half of 2026. miroliverELAP is investigational and not approved for any use.
United Therapeutics (Nasdaq: UTHR) announced the appointment of Kevin J. Tracey, M.D. to its Board of Directors effective January 21, 2026. Dr. Tracey serves as President and CEO of The Feinstein Institutes for Medical Research, Professor of Molecular Medicine and Neurosurgery, and Executive VP, Research at Northwell Health.
He is known for research in inflammation and bioelectronic medicine, discovery of neural circuits controlling immunity, work on monoclonal anti-TNF antibodies, multiple patents, and co-founding biotech companies including SetPoint Medical. United Therapeutics said Dr. Tracey will support its therapeutic pipeline for rare pulmonary diseases and organ manufacturing programs, aligning with the company’s public benefit mission.
United Therapeutics (Nasdaq: UTHR) will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, 1:30–2:10 p.m. PST.
Dr. Martine Rothblatt, chairperson and CEO, will deliver the presentation. A live webcast will be available at https://ir.unither.com/events-and-presentations, with an archived recording posted ~24 hours after the session and accessible for 30 days.
United Therapeutics describes itself as the first publicly traded biotech to adopt a public benefit corporation (PBC) structure, focusing on novel therapies and technologies to expand transplantable organs; more information on the PBC is at unither.com/pbc.
United Therapeutics (Nasdaq: UTHR) announced executives will present at two investor conferences in November 2025. Patrick Poisson, EVP Strategic Development, will speak at the UBS Global Healthcare Conference in Palm Beach on Nov 10, 2025, 9:30–10:05 AM ET. James Edgemond, CFO and Treasurer, will speak at the Jefferies Global Healthcare Conference in London on Nov 18, 2025, 12:00–12:25 PM GMT. Both sessions will be available via live webcast on the company investor site and archived recordings will be posted about 24 hours after each session and accessible for 90 days.
United Therapeutics reiterated its mission as a public benefit corporation to develop novel therapies and organ‑availability technologies. The company provided standard forward‑looking statement cautionary language and dated the information Nov 4, 2025.
United Therapeutics (Nasdaq: UTHR) announced the first transplant in its ongoing EXPAND clinical study of the investigational UKidney xenokidney in patients with end-stage renal disease on November 3, 2025. The operation was performed at NYU Langone Health. The UKidney used in the transplant is from a pig with 10 gene edits: six human genes added to improve immunologic compatibility and four porcine genes knocked out to reduce rejection risk and moderate organ growth.
The company described the trial as a first-of-its-kind effort to evaluate xenotransplantation as an alternative to lifelong dialysis, with stated emphasis on patient safety and continued scientific study.
United Therapeutics (Nasdaq: UTHR) reported record third quarter 2025 results with total revenue $799.5M (up 7% YoY) and net income $338.7M (up 10% YoY) for the quarter ended September 30, 2025.
Product highlights: Total Tyvaso sales were $478.0M (+10% YoY) driven by Tyvaso DPI growth; Orenitram sales were $131.1M (+16% YoY). R&D expense rose to $127.5M (+23% YoY).
Capital actions: The company completed accelerated share repurchases totaling about $2.0B aggregate, with ~2.64M shares delivered in Q3 2025 under ASR agreements.
United Therapeutics (Nasdaq: UTHR) will report third quarter 2025 financial results before market open on Wednesday, October 29, 2025. A press release with results will be issued at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time on the same day.
The live webcast and a one-year rebroadcast will be available at https://ir.unither.com/events-and-presentations. The company reiterates its public benefit corporation purpose and includes customary forward-looking statement cautionary language dated October 15, 2025.
United Therapeutics (Nasdaq: UTHR) announced it will feature clinical data and sponsor events at the CHEST 2025 Annual Meeting in Chicago, October 19–22, 2025.
Two oral rapid‑fire presentations on Oct 21, 2025: 10:44–10:48 AM CDT — interim PHINDER echocardiographic analysis; 2:03–2:07 PM CDT — impact of inhaled treprostinil initiation timing on hospitalizations in PH‑ILD.
Sponsored events include a fellows breakfast (Oct 18), Women in Chest Medicine luncheon (Oct 20), APP networking event (Oct 20), and a PHinding PH symposium (Oct 20, 6:00–9:00 PM CDT).
United Therapeutics (Nasdaq: UTHR) has announced a webcast to present data from their successful TETON-2 pivotal study of nebulized Tyvaso® for treating idiopathic pulmonary fibrosis (IPF). The presentation will take place on September 28, 2025, at 12:30 p.m. ET.
Dr. Steven D. Nathan, Chair of the TETON Steering Committee, will lead the presentation of data previously shown at the European Respiratory Society Congress. The study successfully met its primary endpoint, demonstrating improvement in absolute forced vital capacity (FVC) compared to placebo, with significant improvements also observed in most secondary endpoints.
United Therapeutics (Nasdaq: UTHR), a public benefit corporation, announced that CEO Martine Rothblatt will participate in a fireside chat at the Bernstein 2nd Annual Healthcare Forum in New York. The presentation is scheduled for September 23, 2025, from 1:10 p.m. to 1:50 p.m. EST.
Investors can access the session through a live webcast on the company's website, with a recorded version available for 90 days after the event. As a unique pharmaceutical company structured as a public benefit corporation, United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.